Birchview Capital’s G1 Therapeutics GTHX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-80,000
Closed -$182K – 63
2024
Q2
$182K Hold
80,000
– – 0.17% 50
2024
Q1
$346K Hold
80,000
– – 0.28% 42
2023
Q4
$244K Sell
80,000
-40,000
-33% -$75.2K 0.19% 46
2023
Q3
$173K Buy
120,000
+80,000
+200% +$155K 0.15% 47
2023
Q2
$100K Hold
40,000
– – 0.07% 52
2023
Q1
$107K Hold
40,000
– – 0.08% 51
2022
Q4
$217K Hold
40,000
– – 0.15% 49
2022
Q3
$500K Hold
40,000
– – 0.35% 38
2022
Q2
$198K Hold
40,000
– – 0.14% 52
2022
Q1
$304K Hold
40,000
– – 0.22% 51
2021
Q4
$408K Hold
40,000
– – 0.26% 48
2021
Q3
$537K Hold
40,000
– – 0.37% 38
2021
Q2
$878K Hold
40,000
– – 0.53% 36
2021
Q1
$962K Hold
40,000
– – 0.57% 31
2020
Q4
$720K Hold
40,000
– – 0.41% 34
2020
Q3
$462K Hold
40,000
– – 0.31% 34
2020
Q2
$970K Hold
40,000
– – 0.59% 23
2020
Q1
$441K Hold
40,000
– – 0.39% 31
2019
Q4
$1.06M Hold
40,000
– – 0.77% 20
2019
Q3
$911K Hold
40,000
– – 0.61% 15
2019
Q2
$1.23M Buy
40,000
+25,000
+167% +$526K 0.75% 12
2019
Q1
$249K Hold
15,000
– – 0.16% 43
2018
Q4
$287K Hold
15,000
– – 0.27% 39
2018
Q3
$784K Sell
15,000
-7,000
-32% -$382K 0.51% 21
2018
Q2
$956K Hold
22,000
– – 0.65% 17
2018
Q1
$815K Buy
+22,000
New +$587K 0.54% 16

Birchview Capital's GTHX Position: Q3 2024 in Review

Birchview Capital sold out of G1 Therapeutics (GTHX) in Q3 2024, closing a stake of 80,000 shares — an estimated $182K sold.

Birchview Capital first reported a position in GTHX in Q1 2018 and held it in 26 quarters. The position peaked at $1.23M in Q2 2019. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

  • Birchview Capital reported no remaining G1 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Birchview Capital sold 80,000 G1 Therapeutics shares in Q3 2024, an estimated $182K.
  • Birchview Capital first reported a position in G1 Therapeutics in Q1 2018 and held it in 26 quarters.
  • Birchview Capital's G1 Therapeutics position peaked at $1.23M in Q2 2019.
  • 0 funds tracked by Wall St. Rank held G1 Therapeutics as of Q3 2024.

Based on Birchview Capital's 13F filing for Q3 2024, filed 14 Nov 2024.